A viral vectored prime-boost immunization regime targeting the malaria pfs25 antigen induces transmission-blocking activity

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Goodman, Anna L ^a   Blagborough, Andrew M ^b   Biswas, Sumi ^a   Wu, Yimin ^c   Hill, Adrian V ^a   Sinden, Robert E ^a,b   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MALARIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA VIRUS VECTOR; PFS25 ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR; PARASITE ANTIGEN; PRIMER DNA;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANOPHELES STEPHENSI; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYST; PARASITE PREVALENCE; PARASITE TRANSMISSION; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; ANIMAL; ANOPHELES; DISEASE TRANSMISSION; FLUORESCENT ANTIBODY TECHNIQUE; GENE VECTOR; GENETICS; IMMUNOLOGY; PARASITOLOGY; PATHOGENICITY; VACCINIA VIRUS; WESTERN BLOTTING;

ADENOVIRIDAE; ANOPHELES STEPHENSI; CHIMPANZEE ADENOVIRUS; HUMAN ADENOVIRUS; MUS; PLASMODIUM FALCIPARUM; VACCINIA VIRUS ANKARA;

ANIMALS; ANOPHELES; ANTIGENS, PROTOZOAN; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC VECTORS; MALARIA, FALCIPARUM; MICE; PLASMODIUM FALCIPARUM; VACCINIA VIRUS;

EID: 84555191339     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029428     Document Type: Article

References (57)

1. WHO (2010) World Malaria Report. pp. xii.
2. Lengeler C, (2004) Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev pp. CD000363.
3. Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, et al. (2009) Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 77: 1917-1923.
4. Casares S, Brumeanu TD, Richie TL, (2010) The RTS,S malaria vaccine. Vaccine 28: 4880-4894.
5. Butler D, (2009) Initiative targets malaria eradication. Nature 462: 19.
6. Carter R, (2001) Transmission blocking malaria vaccines. Vaccine 19: 2309-2314.
7. Sinden RE, (2010) A biologist's perspective on malaria vaccine development. Hum Vaccin 6: 3-11.
8. Blagborough AM, Sinden RE, (2009) Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro. Vaccine 27: 5187-5194.
9. Outchkourov N, Vermunt A, Jansen J, Kaan A, Roeffen W, et al. (2007) Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. J Biol Chem 282: 17148-17156.
10. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, et al. (2007) Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc Natl Acad Sci U S A 104: 13461-13466.
11. Vincent AA, Fanning S, Caira FC, Williamson KC, (1999) Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid. Parasite Immunol 21: 573-581.
12. Vermeulen AN, Ponnudurai T, Beckers PJ, Verhave JP, Smits MA, et al. (1985) Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med 162: 1460-1476.
13. Kaslow DC, Isaacs SN, Quakyi IA, Gwadz RW, Moss B, et al. (1991) Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science 252: 1310-1313.
14. Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, et al. (2007) Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A 104: 293-298.
15. Farrance CE, Chichester JA, Musiychuk K, Shamloul M, Rhee A, et al. (2011) Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum Vaccin 7 (Suppl): 191-198.
16. Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, et al. (2007) Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J 6: 107.
17. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, et al. (2008) Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3: e2636.
18. Stowers A, Carter R, (2001) Current developments in malaria transmission-blocking vaccines. Expert Opin Biol Ther 1: 619-628.
19. Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, et al. (2006) Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A 103: 18243-18248.
20. Arakawa T, Tachibana M, Miyata T, Harakuni T, Kohama H, et al. (2009) Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection. Infect Immun 77: 5496-5500.
21. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, et al. (2008) Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14: 819-821.
22. Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, et al. (2009) Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 5: 95-105.
23. Forbes EK, Biswas S, Collins KA, Gilbert SC, Hill AV, et al. (2011) Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference. J Immunol 187: 3738-3750.
24. Biswas S, Dicks MD, Long CA, Remarque EJ, Siani L, et al. (2011) Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One 6: e20977.
25. Goodman AL, Epp C, Moss D, Holder AA, Wilson JM, et al. (2010) New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun 78: 4601-4612.
26. Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, et al. (2010) Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185: 7583-7595.
27. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, et al. (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 6: 78-83.
28. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, et al. (2011) Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Mol Ther.
29. Draper SJ, Heeney JL, (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8: 62-73.
30. Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, et al. (2011) Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine. Vaccine 29: 2720-2726.
31. Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, et al. (1988) A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333: 74-76.
32. Mlambo G, Maciel J, Kumar N, (2008) Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Infect Immun 76: 2018-2024.
33. Ramjanee S, Robertson JS, Franke-Fayard B, Sinha R, Waters AP, et al. (2007) The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 25: 886-894.
34. Mlambo G, Kumar N, Yoshida S, (2010) Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine 28: 7025-7029.
35. Blagborough AM, Yoshida S, Sattabongkot J, Tsuboi T, Sinden RE, (2010) Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 28: 6014-6020.
36. Kumar KA, Oliveira GA, Edelman R, Nardin E, Nussenzweig V, (2004) Quantitative Plasmodium sporozoite neutralization assay (TSNA). J Immunol Methods 292: 157-164.
37. Mlambo G, Kumar N, (2008) Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines. Eukaryot Cell 7: 1875-1879.
38. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
39. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, et al. (2008) Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26: 193-200.
40. Cheru L, Wu Y, Diouf A, Moretz SE, Muratova OV, et al. (2010) The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 28: 4423-4429.
41. de Koning-Ward TF, Janse CJ, Waters AP, (2000) The development of genetic tools for dissecting the biology of malaria parasites. Annu Rev Microbiol 54: 157-185.
42. Sinden RE, (2002) Molecular interactions between Plasmodium and its insect vectors. Cell Microbiol 4: 713-724.
43. Trager W, Jensen JB, (1976) Human malaria parasites in continuous culture. Science 193: 673-675.
44. Ifediba T, Vanderberg JP, (1981) Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature 294: 364-366.
45. Tomas AM, Margos G, Dimopoulos G, van Lin LH, de Koning-Ward TF, et al. (2001) P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. EMBO J 20: 3975-3983.
46. Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, et al. (2010) Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28: 7167-7178.
47. Qian F, Rausch KM, Muratova O, Zhou H, Song G, et al. (2008) Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 26: 2521-2527.
48. Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, et al. (2005) Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun 73: 7375-7380.
49. LeBlanc R, Vasquez Y, Hannaman D, Kumar N, (2008) Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 26: 185-192.
50. Lobo CA, Dhar R, Kumar N, (1999) Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun 67: 1688-1693.
51. Healer J, McGuinness D, Hopcroft P, Haley S, Carter R, et al. (1997) Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infect Immun 65: 3017-3023.
52. Farrance CE, Rhee A, Jones RM, Musiychuk K, Shamloul M, et al. (2011) A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum. Clin Vaccine Immunol 18: 1351-1357.
53. Diallo M, Toure AM, Traore SF, Niare O, Kassambara L, et al. (2008) Evaluation and optimization of membrane feeding compared to direct feeding as an assay for infectivity. Malar J 7: 248.
54. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, et al. (2005) Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23: 3131-3138.
55. de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, et al. (2011) The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187: 2602-2616.
56. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411-1420.
57. Goodman AL, Draper SJ, (2010) Blood-stage malaria vaccines- recent progress and future challenges. Ann Trop Med Parasitol 104: 189-211.